Victrelis® Capsule 200mgImportant Drug Interaction Information

SOL Limited (Singapore Branch) would like to inform healthcare professionals of important drug interaction updates on Victrelis^® (boceprevir). In a pharmacokinetic study evaluating drug interactions between Victrelis^® and ritonavir-boosted HIV protease inhibitors in healthy volunteers, concomitant administration of Victrelis^® with ritonavir in combination with atazanavir or darunavir, or with lopinavir/ritonavir resulted in reduced exposures of the HIV medicines and Victrelis^®, which may be clinically significant for patients infected with both chronic hepatitis C virus (HCV) and HIV. Healthcare professionals treating patients for HCV and HIV should be aware of these drug interactions. Doctors who initiated Victrelis^® in combination with peginterferon alfa and ribavirin in HIV-HCV co-infected patients on fully suppressive antiretroviral therapy containing ritonavir-boosted protease inhibitors should discuss these findings with their patients and monitor them for HCV treatment response and potential HCV and HIV virologic rebound. Please refer to the Dear Healthcare Professional Letter for more information.